Cefpodoxime
PreclinicalSmall molecule
Cefpodoxime is one of 30 small molecule programs targeting Cystitis. It is currently in Preclinical.
2
Indications
2
Total Trials
0
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
22 competitors in Cystitis
#DrugCompanyPhaseTrials
1Ivadantin
PProcter and Gamble
Approved
Monurol
MMeitheal
Approved
Oxytrol
WWim Janssens
Approved
Advil
KKenvue Brands
Approved
Avycaz
PPhiladelphia Eye Associates
Approved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Elmiron
WWim Janssens
Phase 3
Raphamin
MMateria Medica Holding
Phase 3
Gynoflor
MMahidol University
Phase 3
Sodium Hyaluronate
SanofiPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cefpodoxime. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details